Diretrizes para o tratamento da síndrome do anticorpo antifosfolipídeo

Revista Brasileira de Reumatologia

Volumn 53, Issue 2, 2013, Pages 184-192

  Danowski, Adriana ^a   Rego, Jozelia ^b   Kakehasi, Adriana M ^c   Funke, Andreas ^d   De Carvalho, Jozelio Freire ^e   Lima, Isabella V S ^f   De Souza, Alexandre Wagner Silva ^g   Levy, Roger A ^h  

^a Division of Pediatric Surgery and Pediatric Urology Department of Surgery   (Brazil)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^e Centro Médico Alia a   (Brazil)

^f FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^g FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^h STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Anticoagulation; Antiphospholipid syndrome; Pregnancy; Thrombosis; Treatment

Indexed keywords

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BIBLIOGRAPHIC DATABASE; CLINICAL INDICATOR; CLINICAL STUDY; COMPARATIVE STUDY; EVIDENCE BASED MEDICINE; HUMAN; INFORMATION RETRIEVAL; INTERVENTION STUDY; OUTCOME ASSESSMENT; PATIENT; PRACTICE GUIDELINE; QUESTIONNAIRE; SCORING SYSTEM;

ANTICOAGULANT AGENT;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; HUMANS;

EID: 84881520600     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0482-50042013000200005     Document Type: Article

References (42)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update to the classifi cation for defi nite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
2. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007;57(8):1487-95.
3. Ruffatti A, Del Ross T, Ciprian M, Bertero MT, Sciascia S, Scarpato S, et al. Risk factors for afirst thrombotic event in antiphospholipid antibody carriers: a prospective multicenter follow-up study. Ann Rheum Dis. 2011;70(6):1083-6.
4. Cuadrado MJ, Bertolaccini ML, Seed P, Tektonidou M, Aguirre A, Mico L, et al. Primary prevention of thrombosis in Antiphospholipid Antibodies Positive patients: a prospective, multicenter, randomised, open trial comparing low dose aspirin with low dose aspirin plus low intensity oral anticoagulation [abstract]. Arthritis Rheum. 2009;60(Suppl10):1285.
5. Tarr T, Lakos G, Bhattoa HP, Shoenfeld Y, Szegedi G, Kiss E. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus. 2007;16(1):39-45.
6. Ruffatti A, Del Ross T, Ciprian M, Nuzzo M, Rampudda M, Bertero MT, et al. Risk factors for afirst thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis. 2009;68(3):397-9.
7. Hereng T, Lambert M, Hachulla E, Samor M, Dubucquoi S, Caron C, et al. Infl uence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients. Lupus. 2008;17(1):11-5.
8. Erkan D, Harrison MJ, Levy RA, Peterson M, Petri M, Sammaritano L, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibodypositive individuals. Arthritis Rheum. 2007;56(7):2382-91.
9. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 2006;295(9):1050-7.
10. Kaandorp S, Di Nisio M, Goddijn M, Middeldorp S. Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. Cochrane Database Syst Rev. 2009;(1):CD004734.
11. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3(5):848-53.
12. Crowther MA, Wisloff F. Evidence based treatment of the antiphospholipid syndrome II. Optimal anticoagulant therapy for thrombosis. Thromb Res. 2005;115(1-2):3-8.
13. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349(12):1133-8.
14. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332(15):993-7.
15. Rivier G, Herranz MT, Khamashta MA, Hughes GR. Thrombosis and antiphospholipid syndrome: a preliminary assessment of three antithrombotic treatments. Lupus. 1994;3(2):85-90.
16. Derksen RH, de Groot PG, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis. 1993;52(9):689-92.
17. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20:206-18.
18. Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, et al. Antiphospholipid antibodies and subsequent thromboocclusive events in patients with ischemic stroke. JAMA. 2004;291 5 576-84
19. Pengo V, Ruffatti A,Legnani C, Gresele P, Barcellona D, Erba N, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237- 42.
20. Lefévre G, Lambert M, Bacri JL, Dubucquoi S, Quemeneur T, Caron C, et al. Thrombotic events during long-term followup of obstetric antiphospholipid syndrome patients. Lupus. 2011;20(8):861-5.
21. Cervera R, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Kiss E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2009;68(9):1428-32.
22. Erkan D, Merrill JT, Yazici Y, Sammaritano L, Buyon JP, Lockshin MD. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum. 2001;44(6):1466-7.
23. Gris JC, Bouvier S, Molinari N, Galanaud JP, Cochery-Nouvellon E, Mercier E, et al. Comparative incidence of afirst thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood. 2012;119(11):2624-32.
24. Cowchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial. Am J Obstet Gynecol. 1997;176(5):1099-100.
25. Bergrem A, Jacobsen EM, Skjeldestad FE, Jacobsen AF, Skogstad M, Sandset PM. The association of antiphospholipid antibodies with pregnancy-relatedfirst time venous thrombosis - a populationbased case-control study. Thromb Res. 2010;125(5):e222-7.
26. Quenby S, Farquharson RG, Dawood F, Hughes AM, Topping J. Recurrent miscarriage and long-term thrombosis risk: a casecontrol study. Hum Reprod. 2005;20(6):1729-32.
27. Martinez-Zamora MA, Peralta S, Creus M, Tassies D, Reverter JC, Espinosa G, et al. Risk of thromboembolic events after recurrent spontaneous abortion in antiphospholipid syndrome: a casecontrol study. Ann Rheum Dis. 2012;71(1):61-6.
28. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis. 9. Ed. American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e691S-736S.
29. Levy RA, Jesús GR, Jesús NR. Obstetric antiphospholipid syndrome: still a challenge. Lupus. 201019(4):457-9.
30. Derksen RH, De Groot PG, Nieuwenhuis HK, Christiaens GC. How to treat women with antiphospholipid antibodies in pregnancy? Ann Rheum Dis. 2001;60:1-3.
31. Hunt BJ, Gattens M, Khamashta M, Nelson-Piercy C, Almeida A. Thromboprophylaxis with unmonitored intermediate- dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event. Blood Coagul Fibrinolysis. 2003;14:735-9.
32. Hunt BJ, Khamashta M, Lakasing L, Williams FM, Nelson Piercy C, Bewley S, et al. Thromboprophylaxis in antiphospholipid syndrome pregnancies with previous cerebral arterial thrombotic events: is warfarin preferable.Thromb Haemost.1998;79(5):1060-1
33. Pauzner R, Dulitzki M, Langevitz P, Livneh A, Kenett R, Many A. Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy. Thromb Haemost. 2001;86(6):1379-84.
34. Jesus GR, Santos FC, Oliveira CS, Mendes-Silva W, Jesus NR, Levy RA. Management of obstetric antiphospholipid syndrome. Curr Rheumatol Rep. 2012;14(1):79-86.
35. Bramham K, Hunt BJ, Germain S, Calatayud I, Khamashta M, Bewley S, et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus. 2010;19(1):58-64.
36. Alalaf S. Bemiparin versus low dose aspirin for management of recurrent early pregnancy losses due to antiphospholipd antibody syndrome. Arch Gynecol Obstet. 2012;285(3):641-7.
37. Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddell HS, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol. 2000;183(4):1008-12.
38. Laskin CA, Spitzer KA, Clark CA, Crowther MR, Ginsberg JS, Hawker GA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol. 2009;36(2):279-87.
39. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol. 2002;100(3):408-13.
40. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997;314(7076):253-7.
41. Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gómez-Puerta JA, Ramos-Casals M, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006;54(8):2568-76.
42. Cervera R, Bucciarelli S, Plasín MA, Gómez-Puerta JA, Plaza J, Pons-Estel G, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun. 2009;32(3- 4):240-5.